Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Toronto General Hospital, Toronto, Canada.
PLoS One. 2018 Nov 29;13(11):e0207953. doi: 10.1371/journal.pone.0207953. eCollection 2018.
The human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Gay, bisexual, and other men who have sex with men (GBM) living with HIV are disproportionately impacted by HPV-associated anal cancer, with rates about 100-fold that of the general population. Fortunately, HPV vaccination has proven efficacy in preventing both anogenital warts (condyloma) in males and anal pre-cancers (anal intraepithelial neoplasia; AIN) in GBM up to the age of 26. We conducted in-depth, semi-structured interviews with 25 HIV-positive gay men in Toronto to gain an understanding of their knowledge and experiences related to HPV and the HPV vaccine. These participants were part of The HPV Screening and Vaccine Evaluation (HPV-SAVE) Study, and received invitations to have anal cancer screening from their primary care doctors. Interviews were analyzed following a Grounded Theory Approach. Most participants had not received the HPV vaccine. Men described a lack of prior knowledge of the health consequences of HPV for GBM living with HIV and financial barriers to vaccine access. Participants did not articulate concerns about vaccine safety. Men frequently reported initial beliefs that HPV was predominantly-or exclusively-a risk for females or young girls, and thus they had not considered the vaccine to be necessary. Some participants remained uncertain if the current availability of the vaccine, and their newly acquired knowledge of its importance, was "too little, too late" because of their age and/or HPV exposure. Improving access and uptake of HPV vaccination requires addressing both financial barriers to access as well as increasing HPV health literacy levels, particularly by reframing the long-standing gendered associations of HPV. Physicians should provide clear, tailored messages regarding HPV vaccination.
人乳头瘤病毒(HPV)是全球最常见的性传播感染。感染艾滋病毒的男同性恋者、双性恋者和其他与男性发生性关系的男性(GBM)受到 HPV 相关肛门癌的影响不成比例,其发病率是普通人群的约 100 倍。幸运的是,HPV 疫苗已被证明在预防男性肛门生殖器疣(湿疣)和 GBM 中至 26 岁的肛门前癌(肛门上皮内瘤变;AIN)方面具有疗效。我们对多伦多的 25 名感染艾滋病毒的男同性恋者进行了深入的半结构化访谈,以了解他们与 HPV 和 HPV 疫苗相关的知识和经验。这些参与者是 HPV 筛查和疫苗评估(HPV-SAVE)研究的一部分,他们收到了他们的初级保健医生的肛门癌筛查邀请。访谈采用扎根理论方法进行分析。大多数参与者未接种 HPV 疫苗。男性描述了缺乏对 HIV 感染者 GBM 中 HPV 的健康后果的先前知识,以及疫苗接种的经济障碍。参与者没有表达对疫苗安全性的担忧。男性经常报告最初认为 HPV 主要是或专门是女性或年轻女孩的风险,因此他们认为疫苗没有必要。一些参与者仍然不确定当前疫苗的可用性,以及他们新获得的关于疫苗重要性的知识,是否因为他们的年龄和/或 HPV 暴露而“为时过晚”。提高 HPV 疫苗接种的可及性和接种率需要解决获取疫苗的经济障碍以及提高 HPV 健康素养水平,特别是通过重新构建 HPV 长期存在的性别关联。医生应提供有关 HPV 疫苗接种的明确、量身定制的信息。